GSK用20亿美元购买Virobay的潜在NASH治疗,以扩大其肝病治疗。 GSK buys Virobay's potential NASH treatment for $2 billion to expand its liver disease therapies.

GSK已同意一项20亿美元的交易,以便从一家生物技术公司Virobay获得对非酒精牛排肝炎(NASH)的潜在治疗。 GSK has agreed to a $2 billion deal to acquire a potential treatment for Non-Alcoholic Steatohepatitis (NASH) from Virobay, a biotech company. 治疗仍处于早期临床发展阶段,但可以解决肝病治疗方面大量未得到满足的需要。 The treatment is still in early clinical development but could address a significant unmet need in liver disease treatment. 收购是全球创新公司投资创新科学战略的一部分,预计将在2022年初完成,等待监管批准。 The acquisition is part of GSK's strategy to invest in innovative science and is expected to be finalized in early 2022, pending regulatory approval. Virobay的小组将加入GSK的研发单位,继续发展治疗。 Virobay's team will join GSK's R&D unit to continue developing the treatment.